SNY Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 6.54% compared to Sanofi SA's net margin of 15.24%. Sanofi SA's return on equity of 7.55% beat Johnson & Johnson's return on equity of 19.98%.

Sanofi SA has a consensus price target of $63.53, signalling upside risk potential of 10.1%. On the other hand Johnson & Johnson has an analysts' consensus of $169.07 which suggests that it could grow by 3.84%. Given that Sanofi SA has higher upside potential than Johnson & Johnson, analysts believe Sanofi SA is more attractive than Johnson & Johnson.

Sanofi SA has a beta of 0.586, which suggesting that the stock is 41.401% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.473, suggesting its less volatile than the S&P 500 by 52.686%.

Sanofi SA has a quarterly dividend of $2.04 per share corresponding to a yield of 6.82%. Johnson & Johnson offers a yield of 3.05% to investors and pays a quarterly dividend of $1.24 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi SA quarterly revenues are $8.1B, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Sanofi SA's net income of $531.9M is lower than Johnson & Johnson's net income of $3.4B. Notably, Sanofi SA's price-to-earnings ratio is 23.12x while Johnson & Johnson's PE ratio is 28.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 3.01x versus 4.45x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 6.54% compared to Sanofi SA's net margin of -117.16%. Sanofi SA's return on equity of 7.55% beat Moderna's return on equity of -29.09%.

Sanofi SA has a consensus price target of $63.53, signalling upside risk potential of 10.1%. On the other hand Moderna has an analysts' consensus of $54.40 which suggests that it could grow by 57.13%. Given that Moderna has higher upside potential than Sanofi SA, analysts believe Moderna is more attractive than Sanofi SA.

Sanofi SA has a beta of 0.586, which suggesting that the stock is 41.401% less volatile than S&P 500. In comparison Moderna has a beta of 1.863, suggesting its more volatile than the S&P 500 by 86.269%.

Sanofi SA has a quarterly dividend of $2.04 per share corresponding to a yield of 6.82%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi SA quarterly revenues are $8.1B, which are larger than Moderna quarterly revenues of $956M. Sanofi SA's net income of $531.9M is higher than Moderna's net income of -$1.1B. Notably, Sanofi SA's price-to-earnings ratio is 23.12x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 3.01x versus 4.20x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Novavax has a net margin of 6.54% compared to Sanofi SA's net margin of -91.76%. Sanofi SA's return on equity of 7.55% beat Novavax's return on equity of --.

Sanofi SA has a consensus price target of $63.53, signalling upside risk potential of 10.1%. On the other hand Novavax has an analysts' consensus of $16.43 which suggests that it could grow by 105.61%. Given that Novavax has higher upside potential than Sanofi SA, analysts believe Novavax is more attractive than Sanofi SA.

Sanofi SA has a beta of 0.586, which suggesting that the stock is 41.401% less volatile than S&P 500. In comparison Novavax has a beta of 2.916, suggesting its more volatile than the S&P 500 by 191.569%.

Sanofi SA has a quarterly dividend of $2.04 per share corresponding to a yield of 6.82%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi SA quarterly revenues are $8.1B, which are larger than Novavax quarterly revenues of $88.3M. Sanofi SA's net income of $531.9M is higher than Novavax's net income of -$81M. Notably, Sanofi SA's price-to-earnings ratio is 23.12x while Novavax's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 3.01x versus 1.83x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 6.54% compared to Sanofi SA's net margin of 24.22%. Sanofi SA's return on equity of 7.55% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Sanofi SA has a consensus price target of $63.53, signalling upside risk potential of 10.1%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $923.05 which suggests that it could grow by 38.42%. Given that Regeneron Pharmaceuticals has higher upside potential than Sanofi SA, analysts believe Regeneron Pharmaceuticals is more attractive than Sanofi SA.

Sanofi SA has a beta of 0.586, which suggesting that the stock is 41.401% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.270, suggesting its less volatile than the S&P 500 by 72.991%.

Sanofi SA has a quarterly dividend of $2.04 per share corresponding to a yield of 6.82%. Regeneron Pharmaceuticals offers a yield of 0.13% to investors and pays a quarterly dividend of $0.88 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi SA quarterly revenues are $8.1B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Sanofi SA's net income of $531.9M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Sanofi SA's price-to-earnings ratio is 23.12x while Regeneron Pharmaceuticals's PE ratio is 17.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 3.01x versus 5.40x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.